Analysts expect Nuvectra Corp (NASDAQ:NVTR) to announce earnings of ($0.76) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Nuvectra’s earnings, with the highest EPS estimate coming in at ($0.65) and the lowest estimate coming in at ($0.84). Nuvectra posted earnings of ($0.83) per share during the same quarter last year, which would suggest a positive year over year growth rate of 8.4%. The business is expected to issue its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that Nuvectra will report full-year earnings of ($3.03) per share for the current year, with EPS estimates ranging from ($3.35) to ($2.75). For the next fiscal year, analysts expect that the firm will report earnings of ($2.46) per share, with EPS estimates ranging from ($2.53) to ($2.42). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Nuvectra.

Nuvectra (NASDAQ:NVTR) last posted its earnings results on Wednesday, May 1st. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.18). The business had revenue of $11.13 million during the quarter, compared to the consensus estimate of $12.76 million. Nuvectra had a negative return on equity of 62.18% and a negative net margin of 98.77%.

Several analysts recently issued reports on the company. ValuEngine cut Nuvectra from a “hold” rating to a “sell” rating in a research note on Friday, May 3rd. JMP Securities cut their target price on Nuvectra from $26.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Raymond James cut their target price on Nuvectra from $23.00 to $18.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. Finally, BidaskClub cut Nuvectra from a “hold” rating to a “sell” rating in a research note on Tuesday, February 26th. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Nuvectra currently has an average rating of “Hold” and a consensus price target of $20.40.

Shares of NASDAQ NVTR traded down $0.22 during trading hours on Friday, hitting $5.16. The company’s stock had a trading volume of 6,325 shares, compared to its average volume of 328,204. The company has a debt-to-equity ratio of 0.56, a current ratio of 6.60 and a quick ratio of 6.07. The stock has a market capitalization of $93.81 million, a PE ratio of -1.62 and a beta of -0.19. Nuvectra has a 12 month low of $5.18 and a 12 month high of $25.17.

In related news, Director David D. Johnson acquired 20,000 shares of the stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $6.12 per share, for a total transaction of $122,400.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.90% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Cannell Capital LLC raised its position in shares of Nuvectra by 2,750.6% during the 1st quarter. Cannell Capital LLC now owns 723,349 shares of the company’s stock valued at $7,964,000 after buying an additional 697,974 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Nuvectra during the 1st quarter valued at about $1,155,000. Neuberger Berman Group LLC purchased a new stake in shares of Nuvectra during the 1st quarter valued at about $4,392,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Nuvectra during the 1st quarter valued at about $170,000. Finally, Meitav Dash Investments Ltd. purchased a new stake in shares of Nuvectra during the 1st quarter valued at about $2,377,000. Institutional investors and hedge funds own 82.58% of the company’s stock.

Nuvectra Company Profile

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Further Reading: Systematic Risk and Investors

Get a free copy of the Zacks research report on Nuvectra (NVTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.